Zacks Investment Research downgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a hold rating to a sell rating in a research report released on Friday morning, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Other equities analysts have also issued research reports about the company. Barclays assumed coverage on Osmotica Pharmaceuticals in a research note on Tuesday, June 11th. They set an overweight rating and a $11.00 price objective for the company. Wells Fargo & Co set a $14.00 price target on Osmotica Pharmaceuticals and gave the company a buy rating in a research note on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Osmotica Pharmaceuticals presently has an average rating of Buy and an average target price of $14.00.

NASDAQ OSMT opened at $3.31 on Friday. The company’s 50-day moving average is $2.81. The stock has a market cap of $169.50 million and a price-to-earnings ratio of -6.49. Osmotica Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $9.90. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.70 and a quick ratio of 1.41.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.08). The business had revenue of $57.13 million during the quarter, compared to analyst estimates of $53.58 million. Sell-side analysts expect that Osmotica Pharmaceuticals will post -0.25 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the stock. American International Group Inc. purchased a new position in shares of Osmotica Pharmaceuticals in the 4th quarter valued at about $50,000. SG Americas Securities LLC purchased a new position in shares of Osmotica Pharmaceuticals in the 1st quarter valued at about $45,000. Deutsche Bank AG purchased a new position in shares of Osmotica Pharmaceuticals in the 4th quarter valued at about $111,000. Northern Trust Corp purchased a new position in shares of Osmotica Pharmaceuticals in the 4th quarter valued at about $615,000. Finally, Geode Capital Management LLC purchased a new position in shares of Osmotica Pharmaceuticals in the 4th quarter valued at about $668,000. Hedge funds and other institutional investors own 11.64% of the company’s stock.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Featured Story: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.